Interdisciplinary Health Research Team in Musculoskeletal Neoplasia, Canada

Registration Status: Completed

Objective: Interdisciplinary Health Research Team (IHRT) in Musculoskeletal (MSK) Neoplasia is the result of a unique collaboration between clinicians and basic scientists who represent a comprehensive cross-section of geographic and professional constituencies. The health issues under investigation in the application are the pathogenesis, treatment and treatment-related morbidity of primary malignant tumours (sarcomas) of the bones and soft tissues and the benign lesions that are often associated with sarcoma. These diseases affect up to 2% of Canadians1 and represent an important health issue.

Registered Biobank Name	Interdisciplinary Health Research Team in Musculoskeletal Neoplasia
Biobank Leader	Co-Investigators: Dr. Jay Wunder, Dr. Rita Kandel, Dr. Irene Andrulis, Dr. Aileen Davis, Dr. Richard Hill, Dr. David Malkin, Dr. Ben Alman; Associate: Dr. Robert Turcotte, Dr. Bas Masri, Dr. Brian O’Sullivan, Dr. Joel Werier, Dr. Marc Isler
Country	Canada
Email for biobank inquiries	anthony.bozzo.med@ssss.gouv.qc.ca
Principal Investigator	Dr. Robert S. Bell, Department of Surgery, Mount Sinai Hospital
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).